Patheon chief makes quick exit; New Merck CEO's compensation package revealed;

@FiercePharma: 2010 Pharma job cuts cross the 50K mark. Report | Follow @FiercePharma 

> Contract drug manufacturer Patheon said CEO Wesley Wheeler left the company, and Peter Bigelow, president of its North American operations, has stepped in as interim CEO. News

> Incoming Merck CEO Kenneth Frazier's pay package includes a $1.5 million base salary; a target incentive bonus of one-and-a-half times that, or $2.25 million; plus long-term incentive grants worth $7.5 million, for a total of more than $11 million. Article

> Cubist Pharmaceuticals said regulators gave a new approval to its antibiotic Cubicin, allowing Cubist to market a two-minute-injection version of the drug. Story

> GlaxoSmithKline chief Andrew Witty is being lined up to take a key role on the board of the U.K.'s Department for Business, Innovation and Skills (BIS), as part of government plans to gain more input from the private sector. Report

> Eurand agreed to be acquired by Axcan Holdings for $583 million, after an "extended auction process" for the Netherlands specialty pharmaceutical company. Report

> Emami gained as much as 7.3 percent in Mumbai trading after the Times of India reported the company may buy a majority stake in Ahmedabad-based Paras Pharmaceuticals for 30 billion rupees. Item

> The European Medicines Agency has agreed to give greater access to documents on medicines for human and veterinary use, after heavy criticism from the European Ombudsman. News

> Genzyme has completed the sale of Genzyme Genetics to Laboratory Corporation of America Holdings for $925 million in cash. Report

Biotech News

 @FierceBiotech: Pearl Therapeutics drug beats blockbuster COPD drug in PhIIb. News | Follow @FierceBiotech

 @JohnCFierce: GSK is confirming to me that SRT501 is dead. Weak efficacy, renal risks. Now moving on to other formulations. Report | Follow @JohnCFierce

> FDA rejects a new epilepsy drug from Valeant, GSK. Report

> WSJ: Merck ($MRK) to buy SmartCells in $500M deal. Article

Vaccine News

> Experts question potential cholera vax impact on Haiti. Article

Manufacturing News

> J&J plant report renews calls for consent decree. News

> Russia shuts fake Viagra online operation. Report

> Roche, Pfizer deals eye ops jobs preservation. Report

> Genzyme ($GENZ) swats first consent decree pitch. Article

And Finally... Pediatric cancer researchers have identified variations in a gene as important contributors to neuroblastoma, the most common solid cancer of early childhood. Article

Suggested Articles

Colorado is making a play for a Japanese CDMO in hopes it will invest about $100 million in an empty AstraZeneca plant in Boulder.

Esperion's Nexletol has had a rough road to approval after safety concerns nearly derailed its quest. But an FDA nod has the drug ready for market.

The FDA approved Lundbeck's Vyepti, formerly known as eptinezumab, as the first IV therapy to prevent migraines in adults.